UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6301) 6301
Book Chapter (373) 373
Government Document (5) 5
Newspaper Article (5) 5
Book / eBook (1) 1
Conference Proceeding (1) 1
Magazine Article (1) 1
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (5545) 5545
humans (4345) 4345
advanced basic science (3458) 3458
life sciences & biomedicine (3238) 3238
dentistry (2409) 2409
technology (2331) 2331
animals (2329) 2329
materials science (2293) 2293
materials science, biomaterials (2273) 2273
engineering (2260) 2260
engineering, biomedical (2242) 2242
female (2197) 2197
cancer (1824) 1824
male (1787) 1787
oncology (1680) 1680
middle aged (1414) 1414
mice (1341) 1341
aged (1292) 1292
chemotherapy (1154) 1154
adult (1151) 1151
cell line, tumor (1100) 1100
analysis (1022) 1022
tumors (932) 932
treatment outcome (879) 879
care and treatment (824) 824
biological products (797) 797
antineoplastic combined chemotherapy protocols - therapeutic use (642) 642
drug delivery systems (610) 610
medicine & public health (580) 580
drugs (540) 540
health aspects (538) 538
metastasis (523) 523
surgical implants (512) 512
hematology (495) 495
biomedical materials (487) 487
aged, 80 and over (486) 486
cell biology (484) 484
research (476) 476
medicine, research & experimental (463) 463
research & experimental medicine (463) 463
nanoparticles (460) 460
nanoparticles - chemistry (452) 452
antineoplastic agents - therapeutic use (444) 444
prognosis (429) 429
hematology, oncology and palliative medicine (428) 428
mice, inbred balb c (425) 425
pharmacology & pharmacy (416) 416
neoplasm staging (410) 410
vehicles (408) 408
mice, nude (393) 393
patients (389) 389
nanostructure (378) 378
breast cancer (371) 371
cells, cultured (370) 370
neoplasms - drug therapy (370) 370
drug therapy (355) 355
antineoplastic agents (343) 343
rats (342) 342
antineoplastic combined chemotherapy protocols - adverse effects (335) 335
antimitotic agents (331) 331
medical colleges (330) 330
clinical trials (329) 329
disease-free survival (329) 329
cancer therapies (326) 326
stem cells (300) 300
cell line (295) 295
neoplasms - pathology (294) 294
polyethylene glycols - chemistry (292) 292
proteins (279) 279
retrospective studies (278) 278
biocompatibility (275) 275
immunotherapy (273) 273
breast neoplasms - drug therapy (272) 272
gene expression (269) 269
biotechnology & applied microbiology (268) 268
peptides (265) 265
drug delivery (264) 264
surgery (264) 264
survival analysis (264) 264
oncology, experimental (263) 263
breast neoplasms - pathology (261) 261
cancer research (261) 261
cell survival - drug effects (261) 261
other (261) 261
advanced gastric cancer (252) 252
antineoplastic agents - administration & dosage (250) 250
anthracyclines (249) 249
polymers - chemistry (249) 249
survival rate (248) 248
antineoplastic agents - pharmacology (245) 245
advanced cancer (240) 240
particle size (240) 240
apoptosis (236) 236
development and progression (234) 234
fluorescence (232) 232
deoxycytidine - analogs & derivatives (231) 231
mice, inbred c57bl (230) 230
biomedical engineering (226) 226
lung cancer (224) 224
biocompatible materials - chemistry (222) 222
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6673) 6673
Japanese (15) 15
French (5) 5
Chinese (4) 4
German (4) 4
Spanish (4) 4
Korean (3) 3
Russian (2) 2
Italian (1) 1
Portuguese (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Investigational new drugs, ISSN 1573-0646, 12/2016, Volume 35, Issue 2, pp. 180 - 188
Journal Article
Cancer treatment reviews, ISSN 0305-7372, 01/2016, Volume 42, pp. 47 - 55
Highlights • We review advanced thyroid cancer (TC) etiology and signaling pathway mutations. • We review the mechanism of action and role of tyrosine kinase... 
Hematology, Oncology and Palliative Medicine | Refractory | Medullary | Advanced | Multikinase | Survival | Differentiated | Life Sciences & Biomedicine | Oncology | Science & Technology | Thyroid Neoplasms - enzymology | Humans | Receptors, Growth Factor - antagonists & inhibitors | Infant | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Everolimus - administration & dosage | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Quinolines - administration & dosage | Quinolines - pharmacology | Thyroid Neoplasms - therapy | Iodine Radioisotopes - therapeutic use | Multicenter Studies as Topic | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Carcinoma - enzymology | Antineoplastic Agents - pharmacology | Paclitaxel - administration & dosage | Carcinoma - drug therapy | Carboplatin - administration & dosage | Neoplasms - enzymology | Phenylurea Compounds - therapeutic use | Clinical Trials as Topic | Combined Modality Therapy | Thyroidectomy | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Protein Kinase Inhibitors - administration & dosage | Animals | Phenylurea Compounds - administration & dosage | Signal Transduction - drug effects | Thyroid Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Carcinoma - therapy | Mice | Phenylurea Compounds - pharmacology | Protein Kinase Inhibitors - pharmacology | Quinolines - therapeutic use | Quinolines - adverse effects | Development and progression | Thyroid cancer | Tumors | Index Medicus
Journal Article
Investigational new drugs, ISSN 1573-0646, 11/2013, Volume 32, Issue 3, pp. 436 - 444
Journal Article
Oncoimmunology, ISSN 2162-402X, 03/2018, Volume 7, Issue 7, pp. e1438111 - e1438111
Background: Tumor PD-L1 levels have predictive value in PD-1/PD-L1 checkpoint blockade therapies, yet biopsies can only provide baseline information... 
programmed death-ligand 1 (PD-L1) | advanced solid tumor | circulating tumor cells (CTCs) | semi-quantitative analysis | immunotherapy | Oncology | Immunology | Life Sciences & Biomedicine | Science & Technology | circulating tumor cells (ctcs) | programmed death-ligand 1 (pd-l1)
Journal Article
Investigational new drugs, ISSN 1573-0646, 05/2018, Volume 37, Issue 1, pp. 87 - 97
Purpose This phase Ib study (NCT01862328) evaluated the maximum tolerated dose (MTD), safety, and efficacy of pevonedistat in combination with standard-of-care chemotherapies in patients with solid tumors... 
Pevonedistat | Medicine & Public Health | Advanced solid tumors | Oncology | Clinical research | Pharmacology/Toxicology | Phase Ib study | Standard-of-care chemotherapies | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | Prognosis | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Male | Tissue Distribution | Young Adult | Docetaxel - administration & dosage | Aged, 80 and over | Adult | Female | Paclitaxel - administration & dosage | Pyrimidines - administration & dosage | Deoxycytidine - administration & dosage | Carboplatin - administration & dosage | Neoplasms - drug therapy | Maximum Tolerated Dose | NEDD8 Protein - antagonists & inhibitors | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Neoplasms - pathology | Cyclopentanes - administration & dosage | Deoxycytidine - analogs & derivatives | Cohort Studies | Antimitotic agents | Complications and side effects | Dosage and administration | Research | Drug therapy | Antineoplastic agents | Tumors | Thrombocytopenia | Enzymes | Gemcitabine | Toxicity | Liver | Fatigue | Nausea | Patients | Studies | Enzyme inhibitors | Paclitaxel | Carboplatin | ERCC1 protein | Solid tumors | Drug dosages | Neutropenia | Index Medicus | Phase I Studies
Journal Article
Journal Article
Investigational new drugs, ISSN 0167-6997, 2/2015, Volume 33, Issue 1, pp. 159 - 168
...), and recommended phase II dose (RP2D) of tivantinib combined with sorafenib in patients with advanced solid tumors... 
Medicine & Public Health | Sorafenib | VEGF inhibition | Phase I trial | Oncology | Advanced tumors | MET RTK inhibition | Pharmacology/Toxicology | Tivantinib | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | Neoplasms - metabolism | Niacinamide - analogs & derivatives | Proto-Oncogene Proteins c-met - metabolism | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Pyrrolidinones - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Quinolines - administration & dosage | Quinolines - pharmacology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Pyrrolidinones - administration & dosage | Quinolines - pharmacokinetics | Young Adult | Neoplasms - genetics | Phenylurea Compounds - adverse effects | Pyrrolidinones - pharmacology | Aged, 80 and over | Niacinamide - pharmacokinetics | Adult | Female | Phenylurea Compounds - pharmacokinetics | Pyrrolidinones - adverse effects | Niacinamide - adverse effects | Cytochrome P-450 CYP2C19 - genetics | Treatment Outcome | Neoplasms - drug therapy | Niacinamide - administration & dosage | Polymorphism, Genetic | Maximum Tolerated Dose | Phenylurea Compounds - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Phenylurea Compounds - pharmacology | Niacinamide - pharmacology | Quinolines - adverse effects | Chemotherapy, Combination | Usage | Research | Drug therapy | Tumors | Studies | Clinical trials | Inhibitor drugs | Pharmaceutical sciences | Index Medicus | Phase I Studies
Journal Article